Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
1 hedge funds and large institutions have $0 invested in Infinity Pharmaceuticals, Inc. in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.
67% less funds holding
Funds holding: 3 → 1 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
100% less capital invested
Capital invested by funds: $15 → $0 (-$15)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highlander Capital Management
Short Hills,
New Jersey
|
-$9 |
| 2 |
AWM
Able Wealth Management
Toms River,
New Jersey
|
-$5 |
| 3 |
LFA
Livelsberger Financial Advisory
Ashland,
Ohio
|
-$1 |
INFI Hedge Fund Activity: Q1 2024 in Review
1 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q1 2024, worth a combined $0 — down 100% from $15 a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of INFI and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Highlander Capital Management, exiting entirely with an estimated $9 sold.
- 1 institutional investor held Infinity Pharmaceuticals, Inc. (INFI) as of Q1 2024, down from 3 in Q4 2023.
- Funds reported $0 of Infinity Pharmaceuticals, Inc. stock for Q1 2024, down 100% quarter-over-quarter.
- 1 fund opened new Infinity Pharmaceuticals, Inc. positions in Q1 2024 and 3 closed out, a net change of -2 holders.
- The largest Infinity Pharmaceuticals, Inc. seller in Q1 2024 was Highlander Capital Management, an estimated $9 sold.
Based on aggregated 13F filings for Q1 2024.